Clinical Trial Project Management: Which Parts Are Obligations

At a glance

• Most of what is written about clinical trial project management is ordinary project management in a clinical costume. Some of the job is not.
• ICH E6(R3) states separately that the sponsor should ensure sufficient resources, assign appropriately qualified individuals per activity, keep medical expertise readily available, document the financing in an agreement, and notify promptly if a trial is stopped.
• Those five are obligations. Timelines, dashboards and stakeholder maps are not.
• The distinction matters under schedule pressure, because obligations are the things that cannot be traded away and the ones most likely to be, since they look like overheads.

The part of the job that is not negotiable

A clinical trial manager does most of what any project manager does. Scope, schedule, budget, dependencies, status reporting, escalation. That work is real and transferable, and it is what almost every article on this subject describes.

It is also not where trials fail compliance.

ICH E6(R3) does not describe a project management methodology and does not use the term. What it does is place a small number of specific obligations on the sponsor that a trial manager is usually the person actually discharging. Those obligations do not look like deliverables. They look like staffing, availability and paperwork, which is exactly why they erode first when a timeline compresses.

Naming them is useful precisely because it makes them harder to trade away.

Resourcing is a stated obligation, not a budget line

The shortest requirement in this area is also the broadest.

The sponsor should ensure that sufficient resources are available to appropriately conduct the trial (ICH E6(R3) §3.2).

One sentence, and it does not define sufficient. That is not a loophole; it is a judgement the sponsor has to be able to defend. A trial that is underfunded or understaffed relative to what it is trying to do has not met §3.2, whatever the budget approval process concluded.

The practical difference between this and a budget line is who the question is asked of. A budget asks whether the money was approved. §3.2 asks whether the resources are adequate for the trial as designed, which is a question about the trial rather than about the finance process, and it can be answered no for a fully funded study.

Qualified individuals, by activity, and the guideline names them

This is the requirement that most project plans quietly fail.

The sponsor should utilise appropriately qualified individuals for the activities to which they are assigned, for example biostatisticians, clinical pharmacologists, physicians, data scientists and data managers, auditors and monitors, throughout the trial process (ICH E6(R3) §3.4).

Two things are worth pulling out.

The obligation is per activity, not per person. It is not enough for the team to be collectively capable. Each activity needs someone appropriately qualified assigned to it, which means a resourcing plan has to map activities to named capabilities rather than to headcount.

The guideline names the roles. Biostatisticians, clinical pharmacologists, physicians, data scientists and data managers, auditors and monitors. That list is not exhaustive, but it is specific enough to be a test. A plan that assumes a capable generalist covers statistical, pharmacological, medical and data responsibilities has not met §3.4, and the gap usually surfaces at analysis or at inspection rather than during the trial.

“Throughout the trial process” adds the durability requirement. Qualified coverage at kickoff that lapses when someone leaves is not continuing coverage.

Medical expertise, readily available

Called out separately, which is a signal about its weight.

The sponsor should have medical personnel readily available who will be able to advise on specific trial-related medical questions or problems (ICH E6(R3) §3.4.1).

The operative phrase is readily available. This is a staffing requirement with an availability condition attached, and the two come apart constantly. A named medical monitor with no realistic capacity satisfies the org chart and not the requirement. So does one in a timezone that makes same-day advice impossible on a trial that generates urgent questions.

The test is not whether a name exists. It is whether a site with an urgent medical question gets a usable answer in a useful timeframe, and that is a resourcing decision a trial manager usually makes or fails to escalate.

Financing is a contract term

Budget management in most PM writing is forecasting and variance. The requirement is narrower and more concrete.

The financial aspects of the trial should be documented in an agreement between the sponsor and the investigator or institution (ICH E6(R3) §3.5).

Documented, in an agreement. Not agreed verbally and reconciled later, not captured in a budget tool, and not deferred until after activities begin. Where payment terms are still being negotiated while a site is working, the requirement is unmet regardless of how well the eventual contract reads.

This one is easy to satisfy and easy to let slip, because the commercial process and the regulatory requirement are run by different people with different deadlines.

The decision to stop

This is the highest-consequence thing a trial manager sits near, and it is almost entirely absent from project management content about clinical trials.

If a trial is prematurely terminated or suspended, the sponsor should promptly inform the investigators and institutions and the regulatory authorities of the termination or suspension and the reasons for it. The IRB/IEC should also be informed promptly and provided with the reasons, by the sponsor or by the investigator or institution, in accordance with applicable requirements (ICH E6(R3) §3.17.1).

Three audiences, one timing word, and a requirement to give reasons.

Promptly is the constraint that makes this a project management problem rather than a regulatory affairs one. The decision to suspend is often made under pressure, sometimes over a weekend, and the notification obligation attaches immediately rather than after an internal review concludes. A team that has never considered who sends those notifications, to whom, and on what authority will discover the answer at the worst possible moment.

Reasons matter too. The obligation is not satisfied by announcing a stop; it requires telling each audience why.

Worth planning before it is needed, which for most trials means a single page naming the three audiences and the person accountable for each.

Reporting the trial, whether it finished or not

One obligation sits at the other end of the trial and belongs in the same category, because it is a deliverable a trial manager is usually accountable for scheduling.

Whether the trial is completed or prematurely terminated, or an interim analysis is undertaken for regulatory submission, the sponsor should ensure that the clinical trial reports, including interim reports, are prepared and provided to the regulatory authorities (ICH E6(R3) §3.17.2).

Note the first clause. The reporting obligation does not lapse because the trial stopped early. A terminated trial still produces a report, which is not the assumption most closeout plans are built on, and teams that treat premature termination as the end of the work discover the remaining obligation months later with the team already dispersed.

Read together with the notification duty above, a stop decision carries two separate obligations on two different clocks: prompt notification to three audiences, and a report in due course. Planning for the first and forgetting the second is the common pattern.

What is ordinary management, and why saying so helps

Being clear about the boundary cuts both ways. A large part of running a trial carries no specific regulatory requirement:

• timeline construction, critical path analysis and milestone tracking
• status reporting cadence and format
• stakeholder maps and communication plans
• vendor scorecards and KPI dashboards
• meeting structures and escalation paths

These are how you run the work well. None of them is required by name, and treating them as compliance activities inflates the compliance surface without improving it.

The reason to name the boundary is that the five obligations above are the ones that look like overheads. Medical cover that is rarely used, a named biostatistician who is not needed yet, a signed financial agreement before work starts, resources beyond the minimum that would get a site open. Under schedule pressure those are exactly what gets deferred, and each one is a stated requirement rather than a nice-to-have.

A trial manager who knows which five things cannot move is better placed to protect them than one working from a list where everything has equal weight.

Where this sits

Project management is not the trial’s quality system. The sponsor’s risk management cycle, critical-to-quality factors and quality tolerance limits are a separate discipline with its own treatment, and this page deliberately does not reproduce it. Vendor and CRO oversight, and the sequencing of start-up, likewise have their own pages.

What is left, and what this page covers, is narrower than the topic name suggests: the sponsor-side capability a trial has to be able to field, and the one decision nobody plans for until they have to make it.

Sources

• ICH E6(R3) Good Clinical Practice, version R3